Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.

Multiple myeloma is a B-cell malignancy for which no curative therapies exist to date, despite enormous research efforts. The remarkable activity of the proteasome inhibitor bortezomib (PS-341, Velcade) observed in clinical trials of patients with relapsed refractory myeloma has led to investigation...

Full description

Bibliographic Details
Main Authors:	Altun, M, Galardy, P, Shringarpure, R, Hideshima, T, LeBlanc, R, Anderson, K, Ploegh, H, Kessler, B
Format:	Journal article
Language:	English
Published:	2005

Similar Items

Dendritic cells efficiently internalize and process exogenous peptides despite proteasome inhibition.
by: LeBlanc, R, et al.
Published: (2002)

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
by: Berkers, C, et al.
Published: (2005)

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
by: Edwards, C, et al.
Published: (2009)

Detection of ubiquitin-proteasome enzymatic activities in cells: application of activity-based probes to inhibitor development.
by: Kramer, H, et al.
Published: (2012)

Detection of ubiquitin-proteasome enzymatic activities in cells: Application of activity-based probes to inhibitor development
by: Kramer, H, et al.
Published: (2012)

Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy
by: Kang, Jeon Woong, et al.
Published: (2017)

LMP2 expression and proteasome activity in NOD mice.
by: Kessler, B, et al.
Published: (2000)

LMP2 expression and proteasome activity in NOD mice
by: Kessler, B, et al.
Published: (2000)

The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo
by: Edwards, C, et al.
Published: (2007)

Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy.
by: Ovaa, H, et al.
Published: (2003)

Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity.
by: Wang, E, et al.
Published: (2000)

Tight metabolic coupling of the proteasome with downstream oligopeptidases.
by: Wang, E, et al.
Published: (1999)

Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway.
by: Altun, M, et al.
Published: (2010)

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits.
by: Kessler, B, et al.
Published: (2001)

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
by: Chauhan, D, et al.
Published: (2012)

A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14.
by: Borodovsky, A, et al.
Published: (2001)

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
by: Shringarpure, R, et al.
Published: (2006)

Cks1 activates transcription by binding to the ubiquitylated proteasome.
by: Holic, R, et al.
Published: (2010)

IS THE INCIDENCE OF MULTIPLE-MYELOMA REALLY INCREASING
by: Velez, R, et al.
Published: (1981)

Animal models of multiple myeloma
by: Olechnowicz, SWZ, et al.
Published: (2019)

Solid phase synthesis of peptide vinyl sulfone and peptide epoxyketone proteasome inhibitors
by: Overkleeft, H, et al.
Published: (2000)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
by: Lee, HC, et al.
Published: (2024)

Subunit-selective proteasome activity profiling uncovers uncoupled proteasome subunit activities during bacterial infections
by: Misas-Villamil, J, et al.
Published: (2017)

Genomic patterns of progression in smoldering multiple myeloma
by: Bolli, N, et al.
Published: (2018)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

Bone marrow adiposity and multiple myeloma
by: Morris, E, et al.
Published: (2018)

The Bone Marrow Microenvironment in Multiple Myeloma
by: Edwards, C
Published: (2010)

The pathogenesis of the bone disease of multiple myeloma.
by: Edwards, C, et al.
Published: (2008)

The role of BMP signalling in multiple myeloma
by: Gooding, S
Published: (2018)

Lysine demethylase 5A is required for MYC-driven transcription in multiple myeloma
by: Ohguchi, H, et al.
Published: (2021)

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
by: Kurata, K, et al.
Published: (2023)

Initial genome sequencing and analysis of multiple myeloma
by: Chapman, Michael A., et al.
Published: (2014)

Role of the proteasome and non proteasomal proteases in the generation of CTL epitopes.
by: Cerundolo, V, et al.
Published: (1998)

A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome.
by: van Swieten, P, et al.
Published: (2007)

Enzymatic Blockade of the Ubiquitin-Proteasome Pathway
by: Ernst, Robert, et al.
Published: (2011)

Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells.
by: Ovaa, H, et al.
Published: (2004)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

The role of host microenvironment in the pathogenesis of multiple myeloma
by: Lwin, STS
Published: (2014)

Testing novel therapies for the treatment of multiple myeloma
by: Tosun, C
Published: (2023)